Feeble awake effects of plasminogen activator inhibitor type-1 in mice

Hiroyuki Sakakibara; Christoph P N Romanowski; Vladimira Jakubcakova; Cornelia Flachskamm; Kayoko Shimoi; Mayumi Kimura

doi:10.1016/j.bbr.2011.02.023

Feeble awake effects of plasminogen activator inhibitor type-1 in mice

Behav Brain Res. 2011 Jul 7;220(2):354-7. doi: 10.1016/j.bbr.2011.02.023. Epub 2011 Feb 24.

Authors

Hiroyuki Sakakibara¹, Christoph P N Romanowski, Vladimira Jakubcakova, Cornelia Flachskamm, Kayoko Shimoi, Mayumi Kimura

Affiliation

¹ Institute for Environmental Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Japan.

PMID: 21354214
DOI: 10.1016/j.bbr.2011.02.023

Abstract

Plasminogen activator inhibitor-type 1 (PAI-1) is involved in the fibrinolytic system and shows its increased levels in diseases, e.g., obesity and sleep apnea syndrome. The aim of the study is to investigate whether PAI-1 affects sleep-wake patterns in mice. When recombinant mouse PAI-1 was administered intraperitoneally, only rapid but short increases in time spent awake were observed after 20 or 100 μg/kg, although its plasma concentration was kept high for an hour. The results suggest that PAI-1 may serve its role rather as a marker than an initiator of disturbed sleep.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Analysis of Variance
Animals
Brain Waves / drug effects
Dose-Response Relationship, Drug
Electroencephalography / methods
Electromyography / methods
Injections, Intraperitoneal / methods
Male
Mice
Mice, Inbred C57BL
Plasminogen Activator Inhibitor 1 / blood
Plasminogen Activator Inhibitor 1 / pharmacology*
Sleep
Time Factors
Wakefulness / drug effects*

Substances

Plasminogen Activator Inhibitor 1